Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EPS (Weighted Average and Diluted) (2019 - 2026)

Akebia Therapeutics has reported EPS (Weighted Average and Diluted) over the past 7 years, most recently at -$0.05 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 54.55% to -$0.05 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.02 through Dec 2025, up 94.12% year-over-year, with the annual reading at -$0.02 for FY2025, 93.94% up from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.05 for Q4 2025 at Akebia Therapeutics, down from $0.0 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.15 in Q2 2022 and troughed at -$0.51 in Q2 2021.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.08 (2023), against an average of -$0.14.
  • Year-over-year, EPS (Weighted Average and Diluted) crashed 3458.5% in 2024 and then surged 133.33% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.4 in 2021, then soared by 90.0% to -$0.04 in 2022, then soared by 108.19% to $0.0 in 2023, then plummeted by 3458.5% to -$0.11 in 2024, then surged by 54.55% to -$0.05 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's EPS (Weighted Average and Diluted) are -$0.05 (Q4 2025), $0.0 (Q3 2025), and $0.0 (Q2 2025).